GlassScriptPhysician profile
Ilya Rozenberg
NPI 1467460865
$571,742.14
in general payments reported to CMS, 2019-2025
35 companies · $204K in 2025
The $204K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39K · 2022: $79K · 2023: $141K · 2024: $109K · 2025: $204K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $369K · Travel and Lodging: $32K · Consulting Fee: $31K · Food and Beverage: $21K · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $369,282.25 |
| Travel and Lodging | $32,212.24 |
| Consulting Fee | $31,207.00 |
| Food and Beverage | $21,133.53 |
| Education | $173.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $128,449.19 | 2021-2025 | Invega Sustenna, Invega Trinza, Invega |
| Abbvie INC. | $103,104.18 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94,858.74 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $60,769.09 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $52,120.30 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Neurocrine Biosciences, INC. | $50,736.24 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $48,562.81 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $20,863.50 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $6,315.24 | 2023-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $1,546.26 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Allergan, INC. | $1,100.00 | 2021 | |
| Tris Pharma INC | $425.05 | 2021-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $422.81 | 2021-2025 | Trintellix |
| Corium, LLC | $242.12 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $236.27 | 2021-2023 | Belsomra |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $213.65 | 2021-2025 | Aplenzin, Wellbutrin |
| Axsome Therapeutics, INC. | $192.90 | 2022-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $191.80 | 2023-2025 | Quviviq, Quviviq |
| Almatica Pharma LLC | $148.92 | 2022-2025 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $135.52 | 2021-2024 | Qelbree |
| Ironshore Pharmaceuticals INC. | $134.54 | 2023-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $126.65 | 2021-2022 | |
| Eisai INC. | $117.93 | 2021 | |
| Luye Pharma (USA) LTD. | $107.55 | 2025 | Erzofri Extended-Release |
| Collegium Pharmaceutical, INC. | $103.71 | 2025 | Jornay Pm |
| Tempus Ai, INC | $83.61 | 2024 | Tempus Pixel |
| Jazz Pharmaceuticals INC. | $76.60 | 2021-2022 | |
| Indivior INC. | $75.96 | 2022-2024 | Perseris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $71.81 | 2025 | Rexulti |
| Adlon Therapeutics L.P. | $68.35 | 2021 | |
| Avanir Pharmaceuticals, INC. | $66.92 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $20.62 | 2025 | Invega Sustenna |
| Noven Therapeutics, LLC | $19.92 | 2021 | |
| Sage Therapeutics, LLC | $17.37 | 2024 | |
| Tms Neurohealth Centers INC. | $16.01 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilya Rozenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.